BYSI - BeyondSpring reports plinabulin combo data in lung cancer at ASCO meeting 2021

BeyondSpring (BYSI) presents data from a Phase 1 study of plinabulin in combination with nivolumab and ipilimumab in 16 patients for the treatment of 2nd and 3rd line small cell lung cancer ((SCLC)) at the American Society of Clinical Oncology ((ASCO)) Annual Meeting on June 4 - 8, 2021. Plinabulin, in combination with nivolumab and ipilimumab, shows 46% objective response rate ((ORR)) in 13 evaluable patients with PD-1/PD-L1 naïve or resistant tumors in 2nd and 3rd line SCLC.The combination demonstrated favorable safety and tolerability.ORR was 50% for the six patients receiving the triple IO combination as second line therapy after platinum. Three patients had partial responses ((PR)), with best tumor reduction at target lesions of 100%, 53% and 45%, respectively.ORR was 43% for the seven patients receiving the triple IO combination as third line therapy, who had either failed or had not responded to platinum and PD-1/PD-L1 inhibitors. Three patients had PRs,

For further details see:

BeyondSpring reports plinabulin combo data in lung cancer at ASCO meeting 2021